DK0833911T3 - CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf - Google Patents

CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf

Info

Publication number
DK0833911T3
DK0833911T3 DK96922399T DK96922399T DK0833911T3 DK 0833911 T3 DK0833911 T3 DK 0833911T3 DK 96922399 T DK96922399 T DK 96922399T DK 96922399 T DK96922399 T DK 96922399T DK 0833911 T3 DK0833911 T3 DK 0833911T3
Authority
DK
Denmark
Prior art keywords
tissue factor
methods
cdr
cdr grafted
factor antibodies
Prior art date
Application number
DK96922399T
Other languages
Danish (da)
English (en)
Inventor
Robert A Zivin
Linda K Joliffe
Virginia L Pulito
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK0833911T3 publication Critical patent/DK0833911T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96922399T 1995-06-07 1996-06-06 CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf DK0833911T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48012095A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
DK0833911T3 true DK0833911T3 (da) 2004-08-30

Family

ID=23906739

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96922399T DK0833911T3 (da) 1995-06-07 1996-06-06 CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf

Country Status (11)

Country Link
US (4) US7235380B1 (pt)
EP (1) EP0833911B1 (pt)
JP (1) JP4423680B2 (pt)
AT (1) ATE266726T1 (pt)
AU (1) AU716282B2 (pt)
CA (1) CA2223491C (pt)
DE (1) DE69632465T2 (pt)
DK (1) DK0833911T3 (pt)
ES (1) ES2231817T3 (pt)
PT (1) PT833911E (pt)
WO (1) WO1996040921A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
WO2000004148A1 (en) 1998-07-15 2000-01-27 Genentech, Inc. Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
CA2387857A1 (en) 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
EP1829535A3 (en) * 1999-10-27 2007-10-24 Tanox, Inc. Tissue factor antagonists and methods of use thereof
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20040180051A1 (en) * 2001-03-26 2004-09-16 Koji Suzuki Blood rheology improving agents
CN1575302A (zh) * 2001-10-02 2005-02-02 诺沃挪第克公司 人组织因子抗体
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AP2004003113A0 (en) * 2002-02-22 2004-09-30 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
BRPI0410875A (pt) * 2003-05-30 2006-07-04 Centocor Inc método de inibição do crescimento de tumor com anticorpos de fator antitecido
WO2005020927A2 (en) * 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
US7514539B2 (en) 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US7790405B2 (en) 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
MX2008003054A (es) 2005-08-31 2008-03-25 Centocor Inc Lineas de celulas hospederas para la produccion de la region constante de anticuerpos, con fusion efectora mejorada.
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
SI2271670T1 (sl) * 2008-03-14 2015-01-30 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2582728B1 (en) 2010-06-15 2017-08-23 Genmab A/S Human antibody drug conjugates against tissue factor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
EP1263960A2 (en) 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency

Also Published As

Publication number Publication date
EP0833911B1 (en) 2004-05-12
US7235380B1 (en) 2007-06-26
US20080226628A1 (en) 2008-09-18
AU6328296A (en) 1996-12-30
US7777018B2 (en) 2010-08-17
ATE266726T1 (de) 2004-05-15
US20070238869A1 (en) 2007-10-11
CA2223491A1 (en) 1996-12-19
DE69632465T2 (de) 2005-06-23
EP0833911A1 (en) 1998-04-08
US7544790B2 (en) 2009-06-09
DE69632465D1 (de) 2004-06-17
WO1996040921A1 (en) 1996-12-19
AU716282B2 (en) 2000-02-24
PT833911E (pt) 2004-09-30
CA2223491C (en) 2010-08-10
ES2231817T3 (es) 2005-05-16
US20100298544A1 (en) 2010-11-25
JP4423680B2 (ja) 2010-03-03
JPH11507524A (ja) 1999-07-06

Similar Documents

Publication Publication Date Title
DK0833911T3 (da) CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
NO954626L (no) Anti-EGFR-enkeltkjede-Fv-er og anti-EGFR-antistoffer
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
WO2005094446A3 (en) Anti-myostatin antibodies
CR20130156A (es) Proteínas de la unión a il-12/p40 (divisional 9599)
NO2015027I1 (no) Mepolizumab
HK1044159A1 (zh) 抗γ-干擾素的人化抗體
TW200602079A (en) Immunoglobulins
IL158088A (en) Use of an antibody linked to ailim for the preparation of a pharmacological preparation for suppressing or preventing inflammatory bowel disease
ES2113891T3 (es) Anticuerpos monoclonales de raton.
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
UA41984C2 (uk) Спосіб інгібування утворення тромбів у людини (варіанти), спосіб лікування людини для зниження у людини небезпеки постхірургічних тромботичних ускладнень (варіанти),спосіб лікування тромботичного судинного захворювання у людини (варіанти), фармацевтична композиція, що містить некон'юговане антифібринове моноклональне антитіло мн-1, фармацевтична композиція, що містить некон'югований фрагмент або похідне антифібринового моноклонального антитіла мн-1, набір для лікування людини, що потребує інгібування утворення тромбу
MX9709636A (es) Anticuerpos de factor antitisular, injertados en regiones determinadoras de complementariedad, y metodos para su uso.
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
WO2024173865A3 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
WO2005014653A3 (en) Humanized chicken antibodies
WO2024191972A3 (en) Anti-lipocalin-2 antibodies and uses thereof